These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 17473209)

  • 21. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA; Lebwohl D
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
    Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The combination of green tea and tamoxifen is effective against breast cancer.
    Sartippour MR; Pietras R; Marquez-Garban DC; Chen HW; Heber D; Henning SM; Sartippour G; Zhang L; Lu M; Weinberg O; Rao JY; Brooks MN
    Carcinogenesis; 2006 Dec; 27(12):2424-33. PubMed ID: 16785249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
    Nair HB; Kirma NB; Ganapathy M; Vadlamudi RK; Tekmal RR
    Steroids; 2011 Jul; 76(8):792-6. PubMed ID: 21477609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
    Yue W; Wang J; Savinov A; Brodie A
    Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pentagalloylglucose inhibits estrogen receptor alpha by lysosome-dependent depletion and modulates ErbB/PI3K/Akt pathway in human breast cancer MCF-7 cells.
    Hua KT; Way TD; Lin JK
    Mol Carcinog; 2006 Aug; 45(8):551-60. PubMed ID: 16637063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
    Chen J; Power KA; Mann J; Cheng A; Thompson LU
    Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
    Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
    Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
    Long BJ; Jelovac D; Handratta V; Thiantanawat A; MacPherson N; Ragaz J; Goloubeva OG; Brodie AM
    J Natl Cancer Inst; 2004 Mar; 96(6):456-65. PubMed ID: 15026471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xenograft models for aromatase inhibitor studies.
    Brodie A; Sabnis G; Macedo L
    J Steroid Biochem Mol Biol; 2007; 106(1-5):119-24. PubMed ID: 17611101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
    Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
    Schafer JM; Lee ES; O'Regan RM; Yao K; Jordan VC
    Clin Cancer Res; 2000 Nov; 6(11):4373-80. PubMed ID: 11106256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
    Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
    Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
    Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
    Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
    Chen J; Power KA; Mann J; Cheng A; Thompson LU
    Exp Biol Med (Maywood); 2007 Sep; 232(8):1071-80. PubMed ID: 17720953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
    Smollich M; Götte M; Fischgräbe J; Macedo LF; Brodie A; Chen S; Radke I; Kiesel L; Wülfing P
    Breast Cancer Res Treat; 2010 Sep; 123(2):345-57. PubMed ID: 19943105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
    Yoneya T; Tsunenari T; Taniguchi K; Kanbe Y; Morikawa K; Yamada-Okabe H; Lee YH; Lee MH; Kwon LS
    Oncol Rep; 2009 Mar; 21(3):747-55. PubMed ID: 19212635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.